Edition:
United Kingdom

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

110.13USD
4:52pm BST
Change (% chg)

$-0.49 (-0.44%)
Prev Close
$110.62
Open
$111.00
Day's High
$111.14
Day's Low
$110.06
Volume
279,570
Avg. Vol
961,272
52-wk High
$116.61
52-wk Low
$73.70

Chart for

About

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.... (more)

Overall

Beta: 0.35
Market Cap(Mil.): $95,874.12
Shares Outstanding(Mil.): 1,100.99
Dividend: 0.52
Yield (%): 2.39

Financials

  LLY.N Industry Sector
P/E (TTM): 37.74 30.95 32.69
EPS (TTM): 2.31 -- --
ROI: 8.49 14.77 14.32
ROE: 17.03 16.27 16.04

Wall Street stumbles as bond yield climb continues

NEW YORK Wall Street stocks stumbled on Thursday as U.S. Treasury yields continued their ascent to multi-year highs on the latest round of strong economic data, building concerns for an acceleration of inflation. | Video

04 Oct 2018

Boost for 'made in China' medicine as Chi-Med wins key approval

LONDON Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine.

05 Sep 2018

Insurance tactic drags down U.S. drug prices in second quarter: analyst

NEW YORK U.S. drug prices fell again in the second quarter, likely due to a new tactic insurers are using to limit financial assistance drugmakers provide directly to consumers, according to research firm Sector and Sovereign Research (SSR).

04 Sep 2018

UPDATE 1-Insurance tactic drags down U.S. drug prices in 2nd qtr -analyst

NEW YORK, Sept 4 U.S. drug prices fell again in the second quarter, likely due to a new tactic insurers are using to limit financial assistance drugmakers provide directly to consumers, according to research firm Sector and Sovereign Research (SSR).

04 Sep 2018

Deals of the day-Mergers and acquisitions

July 24 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Tuesday:

24 Jul 2018

Lilly plans Elanco IPO, posts quarterly profit above estimates

Eli Lilly and Co said on Tuesday it would take its Elanco animal health business public and posted a better-than-expected quarterly profit, helped by demand for its diabetes drugs Trulicity and Humalog.

24 Jul 2018

Eli Lilly posts quarterly loss

July 24 Eli Lilly and Co posted a second-quarter loss on Tuesday, hurt by acquisition-related charges to the tune of $1.62 billion.

24 Jul 2018

Pfizer-Lilly pain drug meets late-stage trial goals

An experimental osteoarthritis drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of lowering pain in a late stage trial, the companies said on Wednesday, potentially offering a safer alternative to opioids.

18 Jul 2018

Pfizer-Lilly pain drug found effective in late-stage study

July 18 An experimental drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of reducing pain in osteoarthritis patients in a late stage trial, the companies said on Wednesday.

18 Jul 2018

Novo reveals more Ozempic data on change in body weight by baseline BMI

COPENHAGEN, June 23 Diabetes drugmaker Novo Nordisk presented a post-hoc analysis of the SUSTAIN 7 trial comparing treatment effect in body weight across baseline BMI subgroups receiving Novo's Ozempic or Eli Lilly's dulaglutide, marketed as Trulicity.

23 Jun 2018

Competitors

Earnings vs. Estimates